December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,078.66 -1.09 (-0.10%)
Streaming Delayed Price Updated: 2:59 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
New Obesity Medicine Association Initiative Aims to Scale High-Impact Obesity Healthcare Improvements Nationwide
Centennial, Colorado--(Newsfile Corp. - December 18, 2025) - The Obesity Medicine Association (OMA) is pleased to announce a new multi-phase... 
Via Newsfile
News headline image
Eli Lilly’s Oral Obesity Drug Passes Maintenance Test After Wegovy, Zepbound — Wall Street Flags Win For Viking Therapeutics ↗
Lilly’s Orforglipron is eligible for a fast-track review by the FDA in treating obesity. 
Via Stocktwits
News headline image
Better Buy in 2026: Pfizer or Eli Lilly? ↗
These two stocks have been going in opposite directions over the past few years. 
Via The Motley Fool
Topics World Trade
News headline image
Main Street’s High-Stakes Gamble: Retail Traders Double Down as Inflation Cools to 2.7%
NEW YORK — In a stunning reversal of the "higher-for-longer" narrative that dominated much of 2025, the Bureau of Labor Statistics released its November Consumer Price Index (CPI) report today,... 
Via MarketMinute
Topics Artificial Intelligence Economy Regulatory Compliance
News headline image
Why Eli Lilly (LLY) Stock Is Trading Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.2% in the morning session after the company released positive data from its Phase 3 "ATTAIN-MAINTAIN" trial, which evaluated the... 
Via StockStory
News headline image
After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss ↗
Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo. 
Via Benzinga
News headline image
The Weight of a Trillion: Inside Eli Lilly’s Pharmaceutical Hegemony
On this day in late 2025, Eli Lilly and Company (NYSE: LLY) stands as the undisputed titan of the global pharmaceutical industry. Having crossed the historic $1 trillion market capitalization threshold... 
Via PredictStreet
Topics Economy World Trade
News headline image
Eli Lilly's Weight-Loss Pill Succeeds In A First-Of-Its-Kind Study ↗
Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the weight off. 
Via Investor's Business Daily
News headline image
Eli Lilly Scores Another Major Win: Time to Buy? ↗
The company is running circles around its competition. 
Via The Motley Fool
News headline image
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk ↗
These two healthcare stocks have strong growth prospects, but they've been going in opposite directions. 
Via The Motley Fool
News headline image
The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now ↗
It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Cash-Producing Stock for Long-Term Investors and 2 We Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
3 Unstoppable Vanguard ETFs to Buy Even if There's a Stock Market Sell-Off in 2026 ↗
These three growth stock-heavy ETFs offer a contrarian way to invest in a potential stock market sell-off. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector
New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall... 
Via MarketMinute
Topics Intellectual Property
News headline image
1 Bold Prediction for Viking Therapeutics in 2026 ↗
Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it. 
Via The Motley Fool
News headline image
Is Eli Lilly a Buy Before 2026? ↗
Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio. 
Via The Motley Fool
News headline image
Profit Powerhouse: Strong Earnings Outlook Defies Market Slips, Signaling Continued Bull Run for US Stocks
Despite recent pockets of volatility and "slips" in the U.S. stock market during late 2025, a robust corporate profit outlook is emerging as a powerful counter-narrative, fueling investor optimism and... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most ↗
Via MarketBeat
News headline image
Pfizer Adds to Its Big Bet on Weight Loss Drugs ↗
Via MarketBeat
News headline image
Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars ↗
Novo Nordisk's stock has dropped 41% YTD as it lowered sales growth and trimmed 2025 guidance due to competition and patent expiration. 
Via Benzinga
Topics Intellectual Property
News headline image
Where Will Eli Lilly Be in 10 Years? ↗
In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Predictions for Eli Lilly in 2026 ↗
Can anything stop this high-flying drugmaker? 
Via The Motley Fool
News headline image
Here&#39;s How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Why Eli Lilly (LLY) Stock Is Trading Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the stock benefited as investors rotated capital out of the volatile technology sector and into... 
Via StockStory
News headline image
Eli Lilly&#39;s Obesity Drug Dominance Still Underpriced By Market, Bank of America Says ↗
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership. 
Via Benzinga
News headline image
Eli Lilly Just Delivered Fantastic News to Investors ↗
Eli Lilly shares have climbed in the double digits this year. 
Via The Motley Fool
News headline image
Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
2 Predictions for Novo Nordisk in 2026 ↗
The company's worst days might be behind it. 
Via The Motley Fool
News headline image
My Top 3 Healthcare Stocks to Buy in 2026 ↗
These habitual market beaters can pull it off again. 
Via The Motley Fool
News headline image
Eli Lilly Dividend Increase ↗
On Dec. 8, 2025, Eli Lilly increased its dividend by 15.33%, from $1.50 to $1.73 per share. The dividend is payable on March 10, 2026 to shareholders of record on Feb. 13, 2026. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.